Business Wire

Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in Adults

Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada MONTRÉAL--(BUSINESS WIRE)--Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary


Grown Rogue Reports Audited Fiscal Year 2021 Results

2021 Revenue of $9.4M compared to $4.3M in 2020, an increase of 121% 2021 Gross Profit of $5.2M (56% margin), before fair value adjustments, compared to $1.8M (43% margin) in 2020, an increase of 188% and 1300 basis points 2021 aEBITDA1 of $2.2M (24